諾和隆錠２公絲

Ország: Tajvan

Nyelv: kínai

Forrás: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Aktív összetevők:

REPAGLINIDE

Beszerezhető a:

台灣諾和諾德藥品股份有限公司 台北市敦化南路二段２１６號７樓－１ (23528693)

ATC-kód:

A10BX02

Gyógyszerészeti forma:

錠劑

Összetétel:

REPAGLINIDE (6820601100) MG

db csomag:

鋁箔盒裝

Osztály:

製　劑

Recept típusa:

須由醫師處方使用

Gyártó:

NOVO NORDISK A/S NOVO ALLE, DK 2880 BAGSVAERD, DENMARK DK

Terápiás terület:

repaglinide

Terápiás javallatok:

第２型糖尿病（NＩＤＤＭ）無法經由飲食控制、減重及加強運動等方法，達成良好控制者。

Termék összefoglaló:

註銷日期: 2017/03/20; 註銷理由: 自請註銷; 有效日期: 2019/10/19; 英文品名: NOVONORM 2MG TABLETS

Engedélyezési státusz:

已註銷

Engedély dátuma:

1999-10-19

Betegtájékoztató

Code: 100% Direction
Length: Max. 25 mm (100%)
Code end
Regulatory Operations
Insert size: 210x297-003
Current: 4.0
Blister
COLOUR: PMS 280C
8-1765-00-008-1
NOVONORM®
0.5 MG TABLETS
1 MG TABLETS
2 MG TABLETS
Repaglinide
QUALITATIVE AND QUANTITATIVE
COMPOSITION
NovoNorm® contains repaglinide as the
active ingredient. The other ingredients
are listed in_ List of excipients._
The 0.5 mg tablet is white, round and
convex, engraved with Novo Nordisk
logo (Apis bull).
The 1 mg tablet is yellow, round and
convex, engraved with Novo Nordisk
logo (Apis bull).
The 2 mg tablet is peach-coloured,
round and convex, engraved with
Novo Nordisk logo (Apis bull).
PHARMACOTHERAPEUTIC GROUP
Other blood glucose lowering drugs,
excl. insulin.
MANUFACTURER
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd, Denmark
THERAPEUTIC INDICATIONS
Repaglinide is indicated in adults with
type 2 diabetes mellitus whose
hyperglycaemia can no longer be
controlled satisfactorily by diet, weight
reduction and exercise. Repaglinide is
also indicated in combination with
metformin or thiazolidinediones in
adults with type 2 diabetes mellitus who
are not satisfactorily controlled on
repaglinide, metformin or
thiazolidinediones alone. Treatment
should be initiated as an adjunct to diet
and exercise to lower the blood glucose
in relation to meals.
POSOLOGY AND METHOD OF
ADMINISTRATION
POSOLOGY
Repaglinide is given preprandially and is
titrated individually to optimise
glycaemic control. In addition to self-
monitoring by the patient of blood
and/or urinary glucose, the patient’s
blood glucose should be monitored
periodically by the physician to
determine the minimum effective dose
for the patient. Glycosylated
haemoglobin levels are also of value in
monitoring the patient’s response to
therapy. Periodic monitoring is necessary
to detect inadequate lowering of blood
glucose at the recommended maximum
level (i.e. primary failure) and to detect
loss of adequate blood glucose-lowering
response after an initial period of
effectiveness (i.e. secondary failure)